NCT05954780Active, not recruiting
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
A Non-interventional Study of Selinexor (Nexpovio®) in Combination With Bortezomib and Dexamethasone (SVd) in Patients With Relapsed or Refractory Multiple Myeloma (R/RMM)
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine. Thus, SEATTLE will provide real-world evidence complementary to pivotal studies.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 75 (actual)
- First submitted
- 23 Jun 2023
- Start date
- 28 Jun 2023
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- iOMEDICO AG
- Diseases
- Multiple myeloma
- NCT number
- NCT05954780
What you commit to
- Study type: Observational
- Participants enrolled: 75
- From 28 Jun 2023 to the primary completion date, 30 Oct 2026
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindications according to selinexor SmPC for patients with MM
- Participation in an interventional clinical trial
Who the study is looking for
- Relapsed or refractory multiple myeloma
- Indication and decision for ≥2nd-line treatment with selinexor in combination with bortezomib and dexamethasone according to current selinexor SmPC as assessed by the treating physician
- Treatment decision before inclusion into this non-interventional study
- Willingness and ability to participate in the electronic patient-reported outcome (ePRO) module and answering of questionnaires
- Age ≥18 years
- Signed and dated informed consent form
- Inclusion before start of treatment (prospective inclusion)
Age in the registry: 18 years to - · Sex: All
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medizinische Universität Wien, Universitätsklinik für Innere Medizin I Coordinator of this site? Confirm its status | Vienna | Austria | Unknown status |
| Gemeinschaftspraxis für Hämatologie und Onkologie GbR Coordinator of this site? Confirm its status | Ravensburg | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.